GB201614179D0 - Dosage regimen for the treatment of endometriosis - Google Patents

Dosage regimen for the treatment of endometriosis

Info

Publication number
GB201614179D0
GB201614179D0 GBGB1614179.8A GB201614179A GB201614179D0 GB 201614179 D0 GB201614179 D0 GB 201614179D0 GB 201614179 A GB201614179 A GB 201614179A GB 201614179 D0 GB201614179 D0 GB 201614179D0
Authority
GB
United Kingdom
Prior art keywords
endometriosis
treatment
dosage regimen
regimen
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1614179.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mereo Biopharma 2 Ltd
Original Assignee
Mereo Biopharma 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 2 Ltd filed Critical Mereo Biopharma 2 Ltd
Priority to GBGB1614179.8A priority Critical patent/GB201614179D0/en
Publication of GB201614179D0 publication Critical patent/GB201614179D0/en
Priority to JP2019509559A priority patent/JP2019524846A/ja
Priority to CN201780050282.8A priority patent/CN109641057A/zh
Priority to US16/325,872 priority patent/US20190192485A1/en
Priority to EP17757858.0A priority patent/EP3500305A1/en
Priority to PCT/GB2017/052466 priority patent/WO2018033759A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1614179.8A 2016-08-19 2016-08-19 Dosage regimen for the treatment of endometriosis Ceased GB201614179D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB1614179.8A GB201614179D0 (en) 2016-08-19 2016-08-19 Dosage regimen for the treatment of endometriosis
JP2019509559A JP2019524846A (ja) 2016-08-19 2017-08-21 子宮内膜症の治療のための投与レジメン
CN201780050282.8A CN109641057A (zh) 2016-08-19 2017-08-21 用于治疗子宫内膜异位症的剂量方案
US16/325,872 US20190192485A1 (en) 2016-08-19 2017-08-21 Dosage regimen for the treatment of endometriosis
EP17757858.0A EP3500305A1 (en) 2016-08-19 2017-08-21 Dosage regimen for the treatment of endometriosis
PCT/GB2017/052466 WO2018033759A1 (en) 2016-08-19 2017-08-21 Dosage regimen for the treatment of endometriosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614179.8A GB201614179D0 (en) 2016-08-19 2016-08-19 Dosage regimen for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
GB201614179D0 true GB201614179D0 (en) 2016-10-05

Family

ID=57045488

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1614179.8A Ceased GB201614179D0 (en) 2016-08-19 2016-08-19 Dosage regimen for the treatment of endometriosis

Country Status (6)

Country Link
US (1) US20190192485A1 (https=)
EP (1) EP3500305A1 (https=)
JP (1) JP2019524846A (https=)
CN (1) CN109641057A (https=)
GB (1) GB201614179D0 (https=)
WO (1) WO2018033759A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12552754B1 (en) 2025-06-11 2026-02-17 ReproNovo SA Leflutrozole compositions of matter and processes for preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
TW210334B (https=) 1990-12-12 1993-08-01 Ciba Geigy Ag
GB0302572D0 (en) * 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
DE102010003494A1 (de) * 2010-03-31 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose
PT2753312T (pt) * 2011-09-08 2017-02-03 Mereo Biopharma 2 Ltd Utilização de um inibidor da aromatase para o tratamento de hipogonadismo e doenças relacionadas

Also Published As

Publication number Publication date
EP3500305A1 (en) 2019-06-26
CN109641057A (zh) 2019-04-16
US20190192485A1 (en) 2019-06-27
JP2019524846A (ja) 2019-09-05
WO2018033759A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
IL268316B (en) Pharmaceutical preparations for combined treatment
HUE057839T2 (hu) Valbenazin adagolási rendje hiperkinetikus mozgás-zavarok kezelésére
ZA201706007B (en) Pharmaceutical compositions for combination therapy
PL3484451T3 (pl) Postać dawkowana
GB201713653D0 (en) Dosage regimen
IL247084A0 (en) dose fgh–18
GB201411468D0 (en) Novel treatment for endometriosis
IL258228A (en) Combination therapy regimen for treatment of hcv
SG11201803551YA (en) Melflufen dosage regimens for cancer
IL265762A (en) Dosing regimen of avolumab for cancer treatment
GB201418710D0 (en) Dosage regimen
IL266292A (en) treatment regimens
GB201607548D0 (en) Solid dosage form
ZA201800217B (en) Novel dosage regimen tiacumicin compound
IL252774A0 (en) A pharmaceutical preparation for the treatment of fungus
GB201614179D0 (en) Dosage regimen for the treatment of endometriosis
GB201516836D0 (en) Dosing regimen of combination
IL266255A (en) New dosage regimen
HK40008165A (en) Dosage regimen for the treatment of endometriosis
LT3139932T (lt) Gydymo režimas su tiakumicino junginiu
GB201602248D0 (en) Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
GB201602249D0 (en) Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB201521216D0 (en) Dosage regimen

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)